Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer.

Autor: Paik, E Sun1 (AUTHOR) espaik@naver.com, Chang, Ha Kyun2 (AUTHOR), Lee, Sanghoon3 (AUTHOR) mdleesh@korea.ac.kr
Zdroj: Cancers. Jun2023, Vol. 15 Issue 12, p3095. 9p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje